Plain-English translation of NCT04390009 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage research study testing whether advanced whole-body PET-CT imaging scans can help doctors see differences in how the brain is affected by multiple sclerosis. Researchers will use a radioactive tracer called F18-florbetapir and two different types of cutting-edge scanners to look at nerve tissue in people with MS compared to people without the disease. The goal is to gather information that might one day help diagnose or monitor MS more accurately.
Multiple sclerosis damages the protective coating around nerve fibers in the brain and spinal cord, but current ways of detecting this damage have limitations. This study explores whether the newest PET imaging technology can spot these changes more clearly, which could improve how doctors diagnose and track the disease in the future.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will come in for a PET-CT scan where you lie still on a scanner bed while advanced imaging equipment takes pictures of your entire body and brain. The scan takes 10 to 20 minutes. You will also be asked to complete some questionnaires about your mental health and emotional well-being before and after the scan. The study is small and exploratory, involving only 20 participants total.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Brain Health Alliance
Enrollment target
~20 participants
Started
September 2024
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
25 Years – 55 Years
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Carl Taswell, MD, PhD
Brain Health Alliance
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.